The biotechnology sector continues to thrive, with leading firms reporting robust financial performances for 2024. PharmaEssentia Corporation (藥華藥) achieved record earnings per share (EPS) of NT$8.96, positioning itself among high-profitability biotech companies. Meanwhile, agricultural biotech firm Ch Biotech R&d Co., Ltd. Corporation (正瀚) delivered an EPS of NT$4.63, sustaining its strong financial momentum.
PharmaEssentia reported an operating profit of NT$1.736 billion and a net income attributable to shareholders of NT$2.965 billion, resulting in a record-breaking EPS of NT$8.96. The company’s board approved a dividend payout of NT$2.2 per share, split evenly between cash and stock (NT$1.1 each).
PharmaEssentia is set to hold an investor conference on February 27, where it is expected to address ongoing litigation with AOP Orphan Pharmaceuticals and provide insights into its future business strategies.
The company recently announced a significant endorsement from the National Comprehensive Cancer Network (NCCN). The updated NCCN treatment guidelines now recommend alternative long-acting interferons such as Ropeginterferon alfa-2b (Ropeg) in cases where Pegasys is unavailable. CEO Lin Ko-Chung (林國鐘) emphasized that this recognition further solidifies Ropeg’s leadership in the polycythemia vera (PV) market and is expected to accelerate its global market penetration.
Ch Biotech R&d Co., Ltd.’s continued expansion into key international markets has driven its strong financial performance. In 2024, the company reported record consolidated revenue of NT$1.636 billion, representing a 7.98% year-over-year increase. Ch Biotech R&d Co., Ltd. maintained a healthy gross profit margin of 83%, with a net income of NT$476 million and an EPS of NT$4.63.
The company’s board approved a total cash dividend of NT$4.1 per share, which includes a previously distributed NT$0.5 per share interim dividend, resulting in a 100% payout ratio.
Expanding into Southeast and Northeast Asia, Ch Biotech R&d Co., Ltd. has successfully entered the Indonesian market and, by the end of 2024, signed a strategic collaboration with Japan’s Vegetalia Corporation to focus on the rice farming sector through precision agricultural technology. This partnership marks a significant milestone in Ch Biotech R&d Co., Ltd.’s efforts to establish a presence in Japan’s high-value crop sector.
In January, Ch Biotech R&d Co., Ltd. entered a major distribution agreement with Taiwan’s leading agricultural solutions provider, Ch Biotech R&d Co., Ltd. Corporation. The partnership aims to promote Ch Biotech R&d Co., Ltd.’s patented next-generation fertilizer, "Fu (富肽)," targeting Taiwan’s largest crop—rice. This initiative is expected to enhance Ch Biotech R&d Co., Ltd.’s domestic market penetration, support local farmers in boosting yields, and contribute to the modernization of Taiwan’s agricultural industry.
With its strong financial results and strategic expansions, PharmaEssentia and Ch Biotech R&d Co., Ltd. continue to reinforce their positions as key players in their respective fields, poised for further growth in the global biotech and agricultural biotech markets.
Resource: 生技豐收年！藥華藥2024年EPS 8.96元、正瀚4.63元
